ArticleScientific reports2025
miR-378, miR-20a, and miR-520a-3p can be used in a novel serum prognostic panel for cervical cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Due to cervical cancer poor prognosis, discovering prognostic biomarkers is urgently needed. Numerous publications indicated the presence of stable microRNAs (miRNAs) in human serum. This study aimed to identify a specific panel of serum miRNAs that could be used as reliable biomarkers for cervical cancer prognosis evaluation. The candidate miRNAs were measured using quantitative reverse transcription polymerase chain reaction in serum and tissue samples from patients with either favorable (n = 62) or unfavorable (n = 65) prognosis. These miRNAs were correlated with clinical parameters and patients' survival. Functional assays assessed the role of candidate miRNAs in cervical cancer cells. Receiver operating characteristic curves assessed the candidate miRNAs prediction value for cervical cancer prognosis. Compared to the good prognosis group, plasma miR-378 and miR-20a were upregulated, and miR-520a-3p was downregulated in the poor prognosis group. miR-378 and miR-20a were identified as independent risk factors (P = 0.044 and 0.018), both of which promoted C33a cell proliferation, invasion, and migration while suppressing apoptosis. In contrast, miR-520a-3p acted as a protective factor for cervical cancer prognosis (P = 0.018), exhibiting opposing effects on malignant behaviors. The combination of the three miRNAs showed the best prognostic predictive potential for cervical cancer, with an area under curve of 0.907. The serum miRNA biomarker panel (miR-378, miR-20a, and miR-520a-3p) could be used as a non-invasive and accurate prognostic predictor of cervical cancer. This panel could be a promising tool in clinical therapeutic strategies to aid in the timely prediction and management of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.